GSK
GSK
847 hedge funds and large institutions have $11.7B invested in GSK in 2019 Q1 according to their latest regulatory filings, with 112 funds opening new positions, 313 increasing their positions, 263 reducing their positions, and 56 closing their positions.
163% more call options, than puts
Call options by funds: $178M | Put options by funds: $67.7M
100% more first-time investments, than exits
New positions opened: 112 | Existing positions closed: 56
19% more repeat investments, than reductions
Existing positions increased: 313 | Existing positions reduced: 263
12% more capital invested
Capital invested by funds: $10.5B → $11.7B (+$1.22B)
6% more funds holding
Funds holding: 799 → 847 (+48)
0.07% more ownership
Funds ownership: 4.45% → 4.52% (+0.07%)
18% less funds holding in top 10
Funds holding in top 10: 17 → 14 (-3)
Top Buyers
| 1 |
Capital International Investors
Los Angeles,
California
|
+$127M |
| 2 |
Renaissance Technologies
New York
|
+$105M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$68.6M |
| 4 |
Two Sigma Investments
New York
|
+$38.1M |
| 5 |
Charles Schwab
San Francisco,
California
|
+$32.8M |
Top Sellers
GSK Hedge Fund Activity: Q1 2019 in Review
847 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q1 2019, worth a combined $11.7B — up 12% from $10.5B a quarter earlier.
Buyers outnumbered sellers: 112 funds opened new GSK positions and 56 closed out — a net gain of 56 holders — while 313 added to existing stakes and 263 trimmed.
The largest buyer was Capital International Investors, adding an estimated $127M. The largest seller was Royal Bank of Canada, cutting an estimated $226M.
- 847 institutional investors held GSK (GSK) as of Q1 2019, up from 799 in Q4 2018.
- Funds reported $11.7B of GSK stock for Q1 2019, up 12% quarter-over-quarter.
- 112 funds opened new GSK positions in Q1 2019 and 56 closed out, a net change of +56 holders.
- The largest GSK buyer in Q1 2019 was Capital International Investors, an estimated $127M added.
- The largest GSK seller in Q1 2019 was Royal Bank of Canada, an estimated $226M sold.
Based on aggregated 13F filings for Q1 2019.